Fatty acid binding proteins (FABPs) are known central regulators of both metabolic and inflammatory pathways, but their role in tumor development remains largely unexplored. Here, we report that host expression of epidermal FABP (E-FABP) protects against mammary tumor growth. We find that E-FABP is highly expressed in macrophages, particularly in a specific subset, promoting their antitumor activity. In the tumor stroma E-FABP-expressing tumorassociated macrophages (TAMs) produce high levels of interferon β (IFNβ) through upregulation of lipid droplet (LD) formation in response to tumors. E-FABP-mediated IFNβ signaling can further enhance recruitment of tumoricidal effector cells, in particular NK cells, to the tumor stroma for antitumor activity. These findings identify E-FABP as a new protective factor to strengthen IFNβ responses against tumor growth.
Introduction
Fatty acid binding proteins (FABPs) constitute a family of intracellular lipid chaperones coordinating the distribution and function of lipids inside cells (1, 2) . It has been well documented that FABPs play central roles in regulating metabolic and inflammatory pathways in various metabolic and autoimmune diseases (3) (4) (5) (6) (7) . Given the dysregulated metabolic and inflammatory pathways during cancer development, FABPs have been suggested to participate in cancer initiation and progression. However, the exact mechanisms and functions of FABPs in these processes remain largely unknown. In our research focusing on epidermal FABP (E-FABP) functions, we have demonstrated that this protein is highly expressed in immune cells, especially in antigen presenting cells (APCs) and T cells, and regulates both innate and adaptive immune responses (6, 8) . Thus, we propose that E-FABP may link to tumor development through shaping host immune surveillance effects.
There is ample evidence indicating that interferons (IFNs) are critical in mediating immune surveillance to eradicate transformed cells through their effect on host hematopoietic cells (9, 10 ). Recent studies demonstrate that tumors can drive the production of IFNβ by host APCs to induce spontaneous adaptive T cell responses, further supporting the essential role of type I IFNs in antitumor immunity (11, 12) . However, these seminal studies raise a number of important 4 associated macrophages (TAMs) are the most abundant myeloid cells in tumors that exhibit phenotypic and functional heterogeneity (13) (14) (15) . TAMs are classically divided into Th1 cytokine-induced M1 macrophages and Th2 cytokine-induced M2 macrophages. While M1 macrophages have been shown to produce abundant levels of pro-inflammatory cytokines, including type I IFNs, to perform antitumor activities (14, 16) , it remains largely unknown which energetic provider is essential to support their anti-tumor functions.
Because there is high expression of E-FABP in macrophages and E-FABP, as a lipid chaperon, plays a critical role in regulating immune cell functions, we set out to assess whether host expression of E-FABP impacts tumor growth by shaping the function of the immune surveillance process in the present study. Specifically, we determined whether E-FABP displays a unique expression pattern in different subsets of macrophages and how E-FABP regulates specific macrophage antitumor function by focusing on IFNβ production and signaling.
Materials and Methods

Mice and human samples
E-FABP deficient (E-FABP -/-
) and wild type (WT) mice (C57BL/6 background) were bred and maintained in the animal facility of the Hormel Institute in accordance with approved protocols from the Institutional Animal Care and Use Committee (University of Minnesota). Mouse E0771 cells were from CH3 BioSystems; MC38 and RMA cells were gifts from Jun Yan (University of Louisville, KY). All cells were cultured less than 6 months for experiments. Cells were not further authenticated. Invasive breast cancer tissue microarray slides were purchased from US Biomax Inc (Rockville, MD). Human serum samples were collected from patients with benign breast diseases or invasive breast cancers. All patients provided informed consent under an IRB approved protocol.
Syngeneic mouse models
Different dosages of E0771 cells were orthotopically implanted into the mammary fat pad of 6-8 week old WT and E-FABP 
Flow Cytometric analysis and cell sorting
Surface and intracellular staining were performed as previously described (8) . Single immune cell populations in spleens or tumors were separated with a BD FACSAria II Cell Sorter. Flow cytometric analyses were performed with Flowjo (Tree Star). The detailed antibody clone information is shown in the supplemental materials and methods. E0771 cells in a transwell plate for 24h. Total RNA was extracted from tumor-stimulated GM-BMMs using RNeasy Mini Kit (Qiagen) and subjected to mouse mRNA Gene expression by Affymetrix microarray. Microarray analysis was performed using R/Bioconductor packages and signaling pathway was generated with Ingenuity Pathways Analysis (IPA) (Ingenuity Systems). The expression profiling data were submitted to the Gene Expression Omnibus (GSE54073).
Quantitative real-time PCR
RNA was extracted from cultured or purified primary cells using RNeasy Mini Kit (Qiagen).
cDNA synthesis was performed with QuantiTect Reverse Transcription Kit (Qiagen).
Quantitative PCR was performed with SYBR® Green PCR Master Mix using ABI 7500 RealTime PCR Systems (Applied Biosystems). Detailed primer sequences are shown in the supplemental information.
Western Blotting
To quantify the protein levels of E-FABP, A-FABP, phosphorylation and total STAT1 and STAT2, macrophages with designated treatments were lysed in buffers with protease and phosphorylation inhibitors. Protein concentration was determined by BCA assay (Thermo 
Statistical Analysis
For analysis of microarray data, Affy and Limma packages were used to perform the data prepping steps and implement linear models for differential expression. A false discovery rate (FDR) corrected P value was used to filter out the differentially expressed probes. Unpaired, two-tailed Student's t test was performed for the comparison of results from other different treatments. P<0.05 is considered statistically significant.
Results
Host expression of E-FABP suppresses tumor growth
To determine the contribution of host expression of E-FABP to tumor growth, E0771 tumor cells, originally from a C57BL/6 mouse mammary adenocarcinoma (17) 
E-FABP is highly expressed in macrophages
To understand how E-FABP contributes to tumor protection, we first examined the expression profile of E-FABP in naïve mice. F4/80 + macrophages expressed the highest levels of E-FABP among splenic leukocyte subsets, 9 fold higher than adipocytes ( Fig.2A) . Immunostaining of mammary fat tissue ( Fig.2B ) and purified populations from peripheral blood (Fig.2C) showed that E-FABP was also highly expressed in F4/80 + cells. Using bone marrow-derived macrophages, we further confirmed that E-FABP was specifically located in the cytoplasm of WT macrophages, but not in the E-FABP -/-cells ( Fig.2D,2E ). Next, we compared immune cell phenotypes of naïve and E0771 tumor-bearing mice with a focus on TAMs. Compared to spleens and draining lymph nodes (dLNs) in naïve mice, tumor-bearing mice exhibited both enlarged spleens and dLNs with significantly higher numbers of total cells (Supplementary Fig.2A,2B ).
Further analysis showed the enlarged spleens and dLNs were associated with increased Supplementary Fig.2C ). As TAMs play critical roles during cancer development (13, (18) (19) (20) , these results suggest that E-FABP expression in macrophages may protect against tumor growth by promoting their antitumor mechanisms.
Identification of E-FABP expression in specific subsets of macrophages
It is well known that TAMs consist of distinct subpopulations with specialized functions in tumors (21) (22) (23) . We speculated that E-FABP might exhibit unique expression patterns in different subsets of TAMs. First, we used anti-Ly6C and anti-MHCII antibodies to identify distinct subsets of splenic macrophages (CD11b + F4/80 + ) from naïve mice (Fig.3A,3B) , and found that each subset exhibited different levels of CD11c expression (Fig.3C,3D ). Importantly, we demonstrated for the first time that E-FABP was highly expressed in the Q2 and Q3 subsets which exhibited the F4/80
phenotype. In contrast, Q1 and Q4 subsets exhibited no or very low levels of E-FABP expression (Fig.3E) . To further examine the E-FABP expression pattern in TAMs, we collected E0771 tumors from WT and E-FABP -/-mice at different time points. Strikingly, TAM subsets exhibited dynamic changes during tumor development (Fig.3F) . Among the distinct subsets, we found that the Q2 subset, peaking on day 7 after tumor implantation ( Supplementary Fig.3A ), expressed the highest levels of CD11c (Fig.3G ) and E-FABP (Fig.3H) . Although the Q2 subset declined progressively thereafter, E-FABP expression in this subset remained at higher levels relative to the same subset in the spleen during tumor development ( Supplementary Fig.3B ). As the MHCII 
Promotion of IFNβ responses in macrophages by E-FABP
As GM-BMMs expressed high levels of CD11b, F4/80, MHCII, CD11c, and E-FABP expression ( Supplementary Fig.4A-4D ), exhibiting a similar phenotype to E-FABP-expressing TAMs as described above, we thus used GM-BMMs from WT and E-FABP-/-mice to dissect how E- Fig.4B and Supplementary Fig.4F ). Moreover, the levels of secreted IFNβ in supernatants of E-FABP -/-macrophages were significantly lower than that in WT macrophages with stimulation of tumor lysates (Fig.4C) . Knockdown of E-FABP with E-FABP siRNA also inhibited IFNβ production in (Fig.4D,4E) . Altogether, these results indicate that E-FABP is essential to promote IFNβ responses in macrophages.
E-FABP regulates IFNβ responses through controlling lipid droplet formation
Since lipid droplets (LDs) function as platforms to bind Viperin which controls type I IFN induction (26, 27) , we speculate that E-FABP as a lipid transporter may control LD formation to regulate IFNβ responses. As GM-BMMs predominantly expressed E-FABP ( Supplementary   Fig.5A ,5B), we used these cells to dissect the effect of E-FABP-mediated LDs for IFNβ production. Compared to saturated stearic acid, unsaturated oleic/linoleic acids were more effective in enhancing E-FABP expression and LD formation in WT GM-BMMs. More importantly, FA-enhanced LD formation was markedly decreased in the absence of E-FABP in macrophages (Fig.5A ,5B). In line with this observation, the production of Viperin and IFNβ was significantly decreased in E-FABP -/-macrophages as compared to WT macrophages (Fig.5C,5D ). To determine the essential role of LDs for IFNβ production, we inhibited LD formation in macrophages with Triacsin C(28), a potent LD inhibitor ( Supplementary Fig.5C ), and confirmed that LD inhibition indeed impaired IFNβ production in macrophages (Fig.5E ). As oleic acid and linoleic acid are the two most common unsaturated FAs derived from tumor membranes (29), we cocultured macrophages with E0771 tumor cells and demonstrated that E-FABP enhanced LD formation and Viperin production in tumor-stimulated macrophages (Fig.5F,5G ). To measure whether E-FABP regulates IFNβ signaling, we found that E-FABP -/-macrophages exhibited reduced phosphorylation of STAT1 and STAT2 as compared to WT cells in response to IFNβ stimulation (Fig. 5H,5I) . Consistently, when the Q2 subset of TAMs was (Fig.6A-6C) . Notably, the difference disappeared in the late stage of tumor growth (3 weeks post E0771 cell implantation, Fig. 2I ), implying an early effect of E-FABP protection. In addition, E-FABP deficiency had no significant impact on IFNγ production from these infiltrating cells ( Supplementary Fig.6A-6C ). To determine whether these effector cells were responsible for tumor cytotoxicity, we cocultured them with CSFE-labeled tumor cells and demonstrated that effector cells from WT dLNs exhibited higher tumor killing activity than these from E-FABP -/-dLNs (Fig. 6D) . Assays with blocking antibodies specific to CD4, CD8, NK or TRAIL (TNFSF10) suggested that NK cells were the main effector cells in mediating tumor killing in vitro (Fig. 6E) . To confirm this observation, we depleted NK cells in WT and E-FABP -/-mice ( Fig. 6F and Supplementary Fig.6D ) and demonstrated that the tumorsuppressive effect of E-FABP in WT mice diminished in the absence of NK cells (Fig. 6G) . In Fig.7) . Thus, E-FABP-regulated IFNβ signaling in specific TAMs can recruit effector cells, particularly NK cells, for tumor killing.
E-FABP expression in TAMs in human breast cancers
Due to the tumor protective role of E-FABP in mouse models, we next examined whether E-FABP was downregulated in human breast cancers. We analyzed E-FABP expression in normal and malignant breast tissues using publicly accessible microarray data. We found that E-FABP was significantly decreased in various types of breast cancers, including invasive ductal carcinoma, invasive lobular carcinoma and mucinous carcinoma, as compared to normal tissues (Fig.7A) . Interestingly, the statistical significance positively correlated with the sample size (Supplementary Table 2) , suggesting a real effect of E-FABP reduction in breast cancers. By analyzing E-FABP expression in breast stroma tissues with a GEO dataset GSE9014 (20), we found that E-FABP was markedly down-regulated in stroma of invasive human breast tumors as compared to normal stroma ( Fig.7B and Supplementary Table 3) , further corroborating the importance of E-FABP expression in tumor stroma for breast cancer protection. To dissect the location of E-FABP expression in tumor stroma, we used confocal microscopy staining to analyze the expression pattern of E-FABP and TAMs in a tissue microarray containing samples from women with different stages of disease. We found E-FABP was highly expressed in TAMs of women with early stage disease, decreasing with disease progression (Fig.7C,7D) , which was similar to what we observed in mouse models. In addition, we measured circulating levels of E-FABP in patients with benign breast diseases or breast cancer patients and found no differences between them ( Supplementary Fig.8A,8B) Fig.8C, 8D ). These results suggest that circulating E-FABP is not associated with breast cancer development. Altogether, our findings support the idea that E-FABP exerts its protective role through regulation of TAM functions.
Discussion
Compelling evidence from mouse and human studies indicates the importance of immune surveillance of tumors. Thus, how to strengthen host immunity to protect against tumor development remains an area of intense research (32, 33) . It is clear that optimal immune surveillance function depends on appropriate energetic support and homeostasis (34) . We and others have observed that E-FABP is expressed highly in macrophages, less in adipocytes and is barely detectable in non-invasive breast cell lines (35) , indicating that E-FABP plays an important role in regulating macrophage functions. While recent studies suggest that E-FABP ectopic expression in tumor cells can promote their invasive phenotype (36, 37) , our data clearly demonstrate that E-FABP as a cytoplasmic energy carrier enhances the effects of macrophage immune surveillance by promoting LD formation and IFNβ responses in response to tumors.
Thus, E-FABP expression in macrophages represents a new mechanism to protect against tumor growth.
To dissect how E-FABP enhances macrophage antitumor activity, we investigated E-FABP expression in different subsets of macrophages and identified that E-FABP is highly expressed in a specific subset which exhibits the CD11b (Fig.3) . (42) . It has been shown that Viperin, an IFN-stimulated protein, is anchored with its N-terminus α-helix domain to LDs to mediate IFNβ production (43, 44) . Our data provide experimental evidence that macrophage-tumor interaction promotes E-FABP-mediated LD formation and increases Viperin and IFNβ production in macrophages. In contrast, inhibition of LD formation significantly impairs IFNβ production (Fig.5) production in macrophages, which contributes to our increasing understanding of lipid droplet functions (45) .
IFN responses usually consist of two phases: 1) the production of IFNs by innate cells in response to infection, autoimmunity or tumor stimulation, and 2) the binding of secreted IFNs to IFN receptor to activate JAK-STAT signaling and induce IFN-stimulated genes (ISGs) (26) . Our data demonstrate that E-FABP affects not only the production of IFNβ in response to tumors, but also the phosphorylation of STAT1 and STAT2, and the expression of ISGs, such as CXCL10, CXCL11, CCL12, LIPG1 and TNFSF10 (Fig.4,5 indicated from our microarray analyses, it is possible that, compared to E-FABP -/-mice, the reduced tumor lung metastasis in E-FBBP sufficient mice is due to the increased tumor killing in these mice.
Since E-FABP expression strengthens host antitumor immune surveillance, it is logical to speculate that established tumors may exhibit decreased expression of E-FABP. Indeed, E-FABP levels in different types of human breast cancer tissues are significantly lower as compared to normal breast tissues. As our mouse studies indicate that E-FABP is highly expressed in macrophages in tumor stroma, further analysis with human breast stroma tissues demonstrated that E-FABP expression is markedly reduced in the stroma of invasive breast cancers. In addition, we confirmed that E-FABP is mainly expressed in TAMs in human breast cancer tissues and the numbers of E-FABP expressing TAMs are significantly reduced in advanced stages of invasive breast cancers (Fig.7) . While macrophages are generally considered to contribute to tumor progression through enhancing angiogenesis, migration and invasion (15, 48) , our research points out that a specific subset of TAMs, which highly express E-FABP, perform strong antitumor activity.
In summary, we find that E-FABP is highly expressed in a specific subset of macrophages, 
